Lining Arnold Ju

Kanematsu 2016

Testimonial

Diabetes has become one of the major healthcare challenges of the 21st century and a leading cause of clotting diseases such as heart attack and stroke worldwide in which blood flows are obstructed. Unfortunately, the existing anticlotting drugs discovered and developed from intense investigation over the last 40 years are suboptimal, with less than 1 in 6 patients with diabetes taking these therapies avoiding a fatal thrombotic event.

The RCPA Foundation Research Grant-In-Aid enables my research on addressing this pressing need for the identification and development of more effective approaches. It will elucidate a novel biomechanical mechanism that associates with mechanical force generated by dynamic blood flow and leads to enhanced blood clotting in diabetes. The outcome may likely explain the reduced efficacy of current anticlotting drugs (i.e. Aspirin, Plavix® or Brilinta®) in individuals with diabetes, which does not take the 'force effect' into account. Moreover, it will provide an innovative therapeutic strategy to reduce the sticky blood clots of diabetes.